Japanese Gastric Cancer Treatment Guidelines 2018 (5th Edition)

Overview

Journal Gastric Cancer

Specialties Gastroenterology
Oncology

Date 2020 Feb 16

PMID 32060757

Citations 777

Affiliations

Soon will be listed here.

Citing Articles

Prognostic Impact of Fluorescent Lymphography on Gastric Cancer After Neoadjuvant Chemotherapy.

Tang Y, Huang Z, Sun Y, Zhao Y, Qiu W, He J JAMA Surg. 2025; .

PMID: 40072431 PMC: 11904804. DOI: 10.1001/jamasurg.2025.0108.

Nomograms of risk prediction and prognosis for the T1-T2 stage gastric cancer with lymph node metastasis: a population-based study.

Nie G, Geng L, Zhang H, Chu S, Jiang H Front Med (Lausanne). 2025; 12:1492041.

PMID: 40070650 PMC: 11893835. DOI: 10.3389/fmed.2025.1492041.

Comparison of PSOX (paclitaxel, oxaliplatin, S-1) and SOX (oxaliplatin, S-1) as postoperative adjuvant chemotherapy for stage II-III gastric cancer.

Wang F, Huang X, Cao Y, Cao J, Song M, Fang Z World J Surg Oncol. 2025; 23(1):75.

PMID: 40055779 PMC: 11887138. DOI: 10.1186/s12957-025-03723-3.

Comparative study of ICG and non-ICG-guided laparoscopic gastrectomy for gastric cancer: a propensity score-matched analysis at a single center.

Van Du N, Anh Tuan N, Ngoc Cuong L BMJ Surg Interv Health Technol. 2025; 7(1):e000313.

PMID: 40051652 PMC: 11883552. DOI: 10.1136/bmjsit-2024-000313.

Lavage cytology diagnosed by immunostaining may be a poor prognostic factor in pathological stage III colorectal cancer.

Nankaku A, Yamaoka Y, Shiomi A, Kagawa H, Manabe S, Oishi T Ann Gastroenterol Surg. 2025; 9(2):271-280.

PMID: 40046520 PMC: 11877335. DOI: 10.1002/ags3.12863.

References

Hirao M, Masuda K, Asanuma T, Naka H, Noda K, Matsuura K . Endoscopic resection of early gastric cancer and other tumors with local injection of hypertonic saline-epinephrine. Gastrointest Endosc. 1988; 34(3):264-9. DOI: 10.1016/s0016-5107(88)71327-9. View

Kim H, Han S, Kim M, Kim W, Lee H, Ryu S . Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial. JAMA Oncol. 2019; 5(4):506-513. PMC: 6459124. DOI: 10.1001/jamaoncol.2018.6727. View

Katai H, Sasako M, Fukuda H, Nakamura K, Hiki N, Saka M . Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer. 2010; 13(4):238-44. DOI: 10.1007/s10120-010-0565-0. View

Koizumi W, Kim Y, Fujii M, Kim H, Imamura H, Lee K . Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2013; 140(2):319-28. PMC: 3895196. DOI: 10.1007/s00432-013-1563-5. View

Choi J, Kim S, Yoon H, Im J, Kim J, Kim W . Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol. 2013; 12(5):793-800.e1. DOI: 10.1016/j.cgh.2013.09.057. View

Ford H, Marshall A, Bridgewater J, Janowitz T, Coxon F, Wadsley J . Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2013; 15(1):78-86. DOI: 10.1016/S1470-2045(13)70549-7. View

Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M . Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 2016; 20(Suppl 1):69-83. DOI: 10.1007/s10120-016-0663-8. View

Kaminishi M, Yamaguchi H, Shimizu N, Nomura S, Yoshikawa A, Hashimoto M . Stomach-partitioning gastrojejunostomy for unresectable gastric carcinoma. Arch Surg. 1997; 132(2):184-7. DOI: 10.1001/archsurg.1997.01430260082018. View

Sekiguchi M, Suzuki H, Oda I, Abe S, Nonaka S, Yoshinaga S . Favorable long-term outcomes of endoscopic submucosal dissection for locally recurrent early gastric cancer after endoscopic resection. Endoscopy. 2013; 45(9):708-13. DOI: 10.1055/s-0033-1344332. View

10.

Ryu M, Yoo C, Kim J, Ryoo B, Park Y, Park S . Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer. 2015; 51(4):482-488. DOI: 10.1016/j.ejca.2014.12.015. View

11.

Hasuike N, Ono H, Boku N, Mizusawa J, Takizawa K, Fukuda H . A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer. 2017; 21(1):114-123. DOI: 10.1007/s10120-017-0704-y. View

12.

Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T . Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol. 2019; 37(15):1296-1304. PMC: 6524985. DOI: 10.1200/JCO.18.01138. View

13.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

14.

Nakajima T, Oda I, Gotoda T, Hamanaka H, Eguchi T, Yokoi C . Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance?. Gastric Cancer. 2006; 9(2):93-8. DOI: 10.1007/s10120-006-0372-9. View

15.

Tada M, Murakami A, Karita M, Yanai H, Okita K . Endoscopic resection of early gastric cancer. Endoscopy. 1993; 25(7):445-50. DOI: 10.1055/s-2007-1010365. View

16.

Fujitani K, Yang H, Mizusawa J, Kim Y, Terashima M, Han S . Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016; 17(3):309-318. DOI: 10.1016/S1470-2045(15)00553-7. View

17.

Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T . Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG.... J Clin Oncol. 2013; 31(35):4438-44. DOI: 10.1200/JCO.2012.48.5805. View

18.

Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N . Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol. 2010; 67(6):1423-8. DOI: 10.1007/s00280-010-1432-8. View

19.

Thuss-Patience P, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K . Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011; 47(15):2306-14. DOI: 10.1016/j.ejca.2011.06.002. View

20.

. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011; 14(2):113-23. DOI: 10.1007/s10120-011-0042-4. View